Cytiva_APR21_EarlyProcessDevDecisions - 5

EARLY PROCESS DEVELOPMENT DECISIONS PAY OFF FOR CELL AND GENE THERAPIES

More Cell and Gene Therapy Facilities
in the Hundreds are Needed
By Gareth John Macdonald

T

he bioindustry will require more cell and

he said, adding that " if you factor in the plants

gene therapy plants, says an expert, who

needed to make viral vectors that could exceed a

says the facilities of the future must be

thousand facilities. "
The good news, Dasburg says, is that these

automated, scalable, and flexible.

facilities are more like labs than traditional large

The number of cell and gene therapies

biopharmaceutical plants.

entering clinical development has increased

Viral vector capacity is critical to the cell

significantly in recent years. According to the
Alliance for Regenerative Medicines (ARM) there

and gene therapy sector. Vectors are hollow

are 1,066 such therapies in trials at present1,

viruses used to insert genetic material into

which is a 32% increase on the number of studies

cells, both cells used in protein expression

in 2014. But the surge in clinical activity has not

and cells used therapeutically. Various organ-

been matched by an increase in production

isations have voiced concerns about industry

capacity says Darren Dasburg, a cell and gene

capacity to make vectors. In 2018, for example,

therapy-focused consultant.

the Alliance for Advanced Biomedical Engineering said the " scarcity " of viral vectors could

" Hundreds of facilities will be needed to
manufacture the treatments that are in play now, "

hamper expansion2. Since then the situation has

Accelerating Emerging Biotech:
Build your expertise with ours
While you've mastered the science of therapeutic
innovation, we've mastered the art of
bioprocessing. Together, we can help
Watch the
you make good decisions faster.

video

GENengnews.com

|5


https://video.cytivalifesciences.com/watch/3Hptv8ReEyxfUgWw5K7jZy http://www.GENengnews.com

Cytiva_APR21_EarlyProcessDevDecisions

Table of Contents for the Digital Edition of Cytiva_APR21_EarlyProcessDevDecisions

Contents
Cytiva_APR21_EarlyProcessDevDecisions - Cover1
Cytiva_APR21_EarlyProcessDevDecisions - Cover2
Cytiva_APR21_EarlyProcessDevDecisions - Contents
Cytiva_APR21_EarlyProcessDevDecisions - 4
Cytiva_APR21_EarlyProcessDevDecisions - 5
Cytiva_APR21_EarlyProcessDevDecisions - 6
Cytiva_APR21_EarlyProcessDevDecisions - 7
Cytiva_APR21_EarlyProcessDevDecisions - 8
Cytiva_APR21_EarlyProcessDevDecisions - 9
Cytiva_APR21_EarlyProcessDevDecisions - 10
Cytiva_APR21_EarlyProcessDevDecisions - 11
Cytiva_APR21_EarlyProcessDevDecisions - 12
Cytiva_APR21_EarlyProcessDevDecisions - 13
Cytiva_APR21_EarlyProcessDevDecisions - 14
Cytiva_APR21_EarlyProcessDevDecisions - 15
Cytiva_APR21_EarlyProcessDevDecisions - 16
Cytiva_APR21_EarlyProcessDevDecisions - 17
Cytiva_APR21_EarlyProcessDevDecisions - 18
Cytiva_APR21_EarlyProcessDevDecisions - 19
Cytiva_APR21_EarlyProcessDevDecisions - 20
Cytiva_APR21_EarlyProcessDevDecisions - 21
Cytiva_APR21_EarlyProcessDevDecisions - 22
Cytiva_APR21_EarlyProcessDevDecisions - 23
Cytiva_APR21_EarlyProcessDevDecisions - 24
Cytiva_APR21_EarlyProcessDevDecisions - 25
Cytiva_APR21_EarlyProcessDevDecisions - 26
Cytiva_APR21_EarlyProcessDevDecisions - 27
Cytiva_APR21_EarlyProcessDevDecisions - 28
Cytiva_APR21_EarlyProcessDevDecisions - 29
Cytiva_APR21_EarlyProcessDevDecisions - 30
Cytiva_APR21_EarlyProcessDevDecisions - 31
Cytiva_APR21_EarlyProcessDevDecisions - 32
Cytiva_APR21_EarlyProcessDevDecisions - 33
Cytiva_APR21_EarlyProcessDevDecisions - 34
Cytiva_APR21_EarlyProcessDevDecisions - 35
Cytiva_APR21_EarlyProcessDevDecisions - 36
Cytiva_APR21_EarlyProcessDevDecisions - Cover3
Cytiva_APR21_EarlyProcessDevDecisions - Cover4
https://www.nxtbookmedia.com